Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Editorial: Strategies and barriers for hepatitis B cure: implications for HIV

Editorial: Strategies and barriers for hepatitis B cure: implications for HIV Downloaded from http://journals.lww.com/co-hivandaids by BhDMf5ePHKbH4TTImqenVJ2toCr/9wZZjwPUWvYES9l2nY+zyylnl33NGMK6MRsx on 10/02/2020 EDITORIAL URRENT Strategies and barriers for hepatitis B cure: PINION implications for HIV Peter A. Revill and Sharon R. Lewin Chronic hepatitis B and HIV are major public health hope that this series of articles from leading experts challenges for the 21st century, with nearly two in the HBV and HIV fields will inspire new million deaths per year. There is currently no cure approaches and strategies to the elimination/cure for either disease, although recent scientific advan- of both viral infections. ces in our understanding of both viruses and their Chronic HBV infection (CHB) affects at least 257 associated host immune responses provide hope million persons worldwide [3,4], resulting in that a therapeutic cure can be achieved. Strategies 880 000 deaths annually and is a major cause of to achieve cure will likely include direct-acting anti- liver cancer, the second highest cause of cancer- virals and immune-mediated therapy; however, related mortality [9]. The highly effective preventive curative interventions will need to overcome exist- HBV vaccine has had a profound impact on infec- ing barriers likely to prevent fair and equitable dis- tion rates, particularly in children, where birth dose tribution to all http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV & AIDS Wolters Kluwer Health

Editorial: Strategies and barriers for hepatitis B cure: implications for HIV

Download PDF
6 pages

Loading next page...
 
/lp/wolters-kluwer-health/editorial-strategies-and-barriers-for-hepatitis-b-cure-implications-kBtEAjF6l8

References (55)

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0000000000000620
Publisher site
See Article on Publisher Site

Abstract

Downloaded from http://journals.lww.com/co-hivandaids by BhDMf5ePHKbH4TTImqenVJ2toCr/9wZZjwPUWvYES9l2nY+zyylnl33NGMK6MRsx on 10/02/2020 EDITORIAL URRENT Strategies and barriers for hepatitis B cure: PINION implications for HIV Peter A. Revill and Sharon R. Lewin Chronic hepatitis B and HIV are major public health hope that this series of articles from leading experts challenges for the 21st century, with nearly two in the HBV and HIV fields will inspire new million deaths per year. There is currently no cure approaches and strategies to the elimination/cure for either disease, although recent scientific advan- of both viral infections. ces in our understanding of both viruses and their Chronic HBV infection (CHB) affects at least 257 associated host immune responses provide hope million persons worldwide [3,4], resulting in that a therapeutic cure can be achieved. Strategies 880 000 deaths annually and is a major cause of to achieve cure will likely include direct-acting anti- liver cancer, the second highest cause of cancer- virals and immune-mediated therapy; however, related mortality [9]. The highly effective preventive curative interventions will need to overcome exist- HBV vaccine has had a profound impact on infec- ing barriers likely to prevent fair and equitable dis- tion rates, particularly in children, where birth dose tribution to all

Journal

Current Opinion in HIV & AIDS – Wolters Kluwer Health

Published: May 1, 2020

There are no references for this article.